These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 25501829)
41. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Hanson HL; Donermeyer DL; Ikeda H; White JM; Shankaran V; Old LJ; Shiku H; Schreiber RD; Allen PM Immunity; 2000 Aug; 13(2):265-76. PubMed ID: 10981969 [TBL] [Abstract][Full Text] [Related]
42. Adoptive Transfer of CD8+ T Cells Generated from Induced Pluripotent Stem Cells Triggers Regressions of Large Tumors Along with Immunological Memory. Saito H; Okita K; Chang AE; Ito F Cancer Res; 2016 Jun; 76(12):3473-83. PubMed ID: 27197199 [TBL] [Abstract][Full Text] [Related]
43. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer. Cesario A; Rocca B; Rutella S Curr Med Chem; 2011; 18(15):2263-71. PubMed ID: 21517752 [TBL] [Abstract][Full Text] [Related]
44. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Leisegang M; Engels B; Schreiber K; Yew PY; Kiyotani K; Idel C; Arina A; Duraiswamy J; Weichselbaum RR; Uckert W; Nakamura Y; Schreiber H Clin Cancer Res; 2016 Jun; 22(11):2734-43. PubMed ID: 26667491 [TBL] [Abstract][Full Text] [Related]
45. Interleukin-4-induced loss of CD8 expression and cytolytic function in effector CD8 T cells persists long term in vivo. Olver S; Apte SH; Baz A; Kelso A; Kienzle N Immunology; 2013 Jun; 139(2):187-96. PubMed ID: 23311920 [TBL] [Abstract][Full Text] [Related]
46. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Zhou Q; Schneider IC; Edes I; Honegger A; Bach P; Schönfeld K; Schambach A; Wels WS; Kneissl S; Uckert W; Buchholz CJ Blood; 2012 Nov; 120(22):4334-42. PubMed ID: 22898597 [TBL] [Abstract][Full Text] [Related]
47. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Minagawa A; Yoshikawa T; Yasukawa M; Hotta A; Kunitomo M; Iriguchi S; Takiguchi M; Kassai Y; Imai E; Yasui Y; Kawai Y; Zhang R; Uemura Y; Miyoshi H; Nakanishi M; Watanabe A; Hayashi A; Kawana K; Fujii T; Nakatsura T; Kaneko S Cell Stem Cell; 2018 Dec; 23(6):850-858.e4. PubMed ID: 30449714 [TBL] [Abstract][Full Text] [Related]
48. Monoclonal TCR-redirected tumor cell killing. Liddy N; Bossi G; Adams KJ; Lissina A; Mahon TM; Hassan NJ; Gavarret J; Bianchi FC; Pumphrey NJ; Ladell K; Gostick E; Sewell AK; Lissin NM; Harwood NE; Molloy PE; Li Y; Cameron BJ; Sami M; Baston EE; Todorov PT; Paston SJ; Dennis RE; Harper JV; Dunn SM; Ashfield R; Johnson A; McGrath Y; Plesa G; June CH; Kalos M; Price DA; Vuidepot A; Williams DD; Sutton DH; Jakobsen BK Nat Med; 2012 Jun; 18(6):980-7. PubMed ID: 22561687 [TBL] [Abstract][Full Text] [Related]
49. Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization. Newick K; O'Brien S; Sun J; Kapoor V; Maceyko S; Lo A; Puré E; Moon E; Albelda SM Cancer Immunol Res; 2016 Jun; 4(6):541-51. PubMed ID: 27045023 [TBL] [Abstract][Full Text] [Related]
50. Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Sierra RA; Thevenot P; Raber PL; Cui Y; Parsons C; Ochoa AC; Trillo-Tinoco J; Del Valle L; Rodriguez PC Cancer Immunol Res; 2014 Aug; 2(8):800-11. PubMed ID: 24830414 [TBL] [Abstract][Full Text] [Related]
51. Tumor size at the time of adoptive transfer determines whether tumor rejection occurs. Cordaro TA; de Visser KE; Tirion FH; Graus YM; Haanen JB; Kioussis D; Kruisbeek AM Eur J Immunol; 2000 May; 30(5):1297-307. PubMed ID: 10820375 [TBL] [Abstract][Full Text] [Related]
52. Detection and analysis of antigen-specific CD8+ T cells. Badovinac VP; Harty JT Immunol Res; 2001; 24(3):325-32. PubMed ID: 11817329 [TBL] [Abstract][Full Text] [Related]
53. Designing TCR for cancer immunotherapy. Voss RH; Kuball J; Theobald M Methods Mol Med; 2005; 109():229-56. PubMed ID: 15585925 [TBL] [Abstract][Full Text] [Related]
54. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo. Spranger S; Jeremias I; Wilde S; Leisegang M; Stärck L; Mosetter B; Uckert W; Heemskerk MH; Schendel DJ; Frankenberger B Blood; 2012 Apr; 119(15):3440-9. PubMed ID: 22371883 [TBL] [Abstract][Full Text] [Related]
55. Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes. Klevorn LE; Berrien-Elliott MM; Yuan J; Kuehm LM; Felock GD; Crowe SA; Teague RM Cancer Immunol Res; 2016 Dec; 4(12):1016-1026. PubMed ID: 27803062 [TBL] [Abstract][Full Text] [Related]